Literature DB >> 9574793

Three probable cases of Loa loa encephalopathy following ivermectin treatment for onchocerciasis.

M Boussinesq1, J Gardon, N Gardon-Wendel, J Kamgno, P Ngoumou, J P Chippaux.   

Abstract

Over the past nine years, more than 12 million people exposed to Onchocerca volvulus infection have received at least one dose of ivermectin, almost all without serious adverse reactions. Since 1991, however, several cases with neurologic manifestations, including coma, have been reported after ivermectin treatment of persons infected with O. volvulus who also had concomitant Loa loa infection with very high microfilaremia (> 50,000 microfilariae/ml of blood). In 1995, four criteria were established to define probable cases of Loa encephalopathy temporally related to treatment with ivermectin (PLERI). The present paper describes three PLERI cases recorded in Cameroon and compares them with two others reported previously. Disorders of consciousness began 3-4 days after treatment. The objective neurologic signs were variable. The conditions improved favorably in three patients who benefited from early hospitalization and good nursing; their disorders of consciousness lasted only 2-3 days; the results of clinical examination became normal after one month and electroencephalographic abnormalities disappeared after 5-7 months. Conversely, late diagnosis and delay in proper management in two others probably led to worsening of the condition and to fatal outcome related to the usual complications of coma. In addition to these cases, patients w with high Loa microfilaremia also developed milder neurologic manifestations causing functional impairment lasting for at least one week after treatment. Before launching mass ivermectin distribution programs to control onchocerciasis in central Africa, communities in which the intensity of concomitant L. loa microfilaremia is high need to be identified, and specific educational measures and monitoring strategies should be developed and applied before they are treated.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9574793     DOI: 10.4269/ajtmh.1998.58.461

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  57 in total

1.  Modeling targeted ivermectin treatment for controlling river blindness.

Authors:  Eric M Poolman; Alison P Galvani
Journal:  Am J Trop Med Hyg       Date:  2006-11       Impact factor: 2.345

2.  Potential Role for Flubendazole in Limiting Filariasis Transmission: Observations of Microfilarial Sensitivity.

Authors:  Maeghan O'Neill; Jelil Abdel Njouendou; Michael Dzimianski; Erica Burkman; Patrick Chouna Ndongmo; Jonas A Kengne-Ouafo; Samuel Wanji; Andrew Moorhead; Charles D Mackenzie; Timothy G Geary
Journal:  Am J Trop Med Hyg       Date:  2018-01       Impact factor: 2.345

3.  Clinical Features of Imported Loiasis: A Case Series from the Hospital for Tropical Diseases, London.

Authors:  Makoto Saito; Margaret Armstrong; Samuel Boadi; Patricia Lowe; Peter L Chiodini; Tom Doherty
Journal:  Am J Trop Med Hyg       Date:  2015-06-22       Impact factor: 2.345

Review 4.  Mining Filarial Genomes for Diagnostic and Therapeutic Targets.

Authors:  Sasisekhar Bennuru; Elise M O'Connell; Papa M Drame; Thomas B Nutman
Journal:  Trends Parasitol       Date:  2017-10-12

Review 5.  Ivermectin for onchocercal eye disease (river blindness).

Authors:  Henry O D Ejere; Ellen Schwartz; Richard Wormald; Jennifer R Evans
Journal:  Cochrane Database Syst Rev       Date:  2012-08-15

6.  In vitro activities of plant extracts on human Loa loa isolates and cytotoxicity for eukaryotic cells.

Authors:  Line-Edwige Mengome; Jean Paul Akue; Alain Souza; Guy Raymond Feuya Tchoua; Edouard Nsi Emvo
Journal:  Parasitol Res       Date:  2010-05-22       Impact factor: 2.289

7.  Rapid, novel, specific, high-throughput assay for diagnosis of Loa loa infection.

Authors:  Peter D Burbelo; Roshan Ramanathan; Amy D Klion; Michael J Iadarola; Thomas B Nutman
Journal:  J Clin Microbiol       Date:  2008-05-28       Impact factor: 5.948

Review 8.  Moxidectin and the avermectins: Consanguinity but not identity.

Authors:  Roger Prichard; Cécile Ménez; Anne Lespine
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2012-04-14       Impact factor: 4.077

9.  Implications for annual retesting after a test-and-not-treat strategy for onchocerciasis elimination in areas co-endemic with Loa loa infection: an observational cohort study.

Authors:  Sébastien Ds Pion; Hugues Nana-Djeunga; Yannick Niamsi-Emalio; Cédric B Chesnais; Hugo Deléglise; Charles Mackenzie; Wilma Stolk; Daniel A Fletcher; Amy D Klion; Thomas B Nutman; Michel Boussinesq; Joseph Kamgno
Journal:  Lancet Infect Dis       Date:  2019-10-31       Impact factor: 25.071

Review 10.  Development of emodepside as a possible adulticidal treatment for human onchocerciasis-The fruit of a successful industrial-academic collaboration.

Authors:  Jürgen Krücken; Lindy Holden-Dye; Jennifer Keiser; Roger K Prichard; Simon Townson; Benjamin L Makepeace; Marc P Hübner; Steffen R Hahnel; Ivan Scandale; Achim Harder; Daniel Kulke
Journal:  PLoS Pathog       Date:  2021-07-22       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.